Test Performance in Screening - Genetics

1. A laboratory is developing a quantitative assay for a biomarker associated with a genetic disorder. To minimize the number of missed diagnoses for this serious but treatable condition, the clinical team decides to lower the diagnostic cutoff value for a positive result. What is the most likely consequence of this adjustment on the test's performance characteristics?
   Answer: Sensitivity will increase and specificity will decrease. Lowering the diagnostic cutoff means that a lower level of the biomarker is now considered positive. This will result in more individuals with the disease being correctly identified (increasing True Positives), thus increasing sensitivity. However, it will also cause more individuals without the disease to be incorrectly classified as positive (increasing False Positives), thus decreasing specificity. The false negative rate (1 - sensitivity) will decrease, not increase.
2. Two labs independently validate the same genetic test. Lab A reports a sensitivity of 92% (8% false negatives). Lab B reports a false negative rate of 8%. Both labs test populations with similar disease characteristics. Based on this information, which conclusion is most justified?
   Answer: The tests from the two labs have identical sensitivity. When you encounter genetic test validation questions, focus on the precise definitions of sensitivity, specificity, and error rates. These terms have exact mathematical relationships that don't change between labs. Sensitivity measures a test's ability to correctly identify positive cases, calculated as: $\text{Sensitivity} = \frac{\text{True Positives}}{\text{True Positives + False Negatives}}$. The false negative rate is simply 100% minus sensitivity. If Lab A has 92% sensitivity, its false negative rate is 8%. Lab B directly reports an 8% false negative rate, meaning its sensitivity is also 92%. Therefore, both tests have identical sensitivity, making answer A correct. Answer B is wrong because we have no information about specificity, which relates to false positive rates and true negatives—completely separate from the sensitivity data given. Answer C is incorrect for the same reason; false positive rates depend on specificity, not sensitivity. We cannot determine anything about false positives from the provided information. Answer D is flawed because disease prevalence in the tested populations doesn't affect the intrinsic performance characteristics of the tests themselves. Sensitivity and specificity are properties of the test, not the population. Study tip: Remember that sensitivity = 100% - false negative rate, and specificity = 100% - false positive rate. These are fixed test characteristics. Don't confuse them with prevalence, which describes the population being tested. On genetics exams, always identify which test performance metric is actually being discussed before drawing conclusions.
3. A screening program tested 20,000 individuals for a genetic condition. The test has a sensitivity of 80% and a specificity of 95%. If the true prevalence of the condition in this population is 1%, how many true negative results are expected?
   Answer: 18,810 This requires multiple steps. First, calculate the number of individuals with and without the condition. With condition: 1% of 20,000 = 200. Without condition: 99% of 20,000 = 19,800. True negatives are found within the group without the condition. The number of true negatives is calculated by multiplying the number of disease-free individuals by the specificity. Number of True Negatives = 19,800 * 0.95 = 18,810.
4. A screening test for a genetic disorder yields 30 false negative results in a study cohort. The calculated sensitivity of the test was 85%. How many individuals in the cohort truly had the disorder?
   Answer: 200 This requires working backwards. Sensitivity = TP / (TP + FN). A sensitivity of 85% means the false negative rate is 100% - 85% = 15%. The false negative rate is defined as FN / (Total with disease). We are given that FN = 30. So, 0.15 = 30 / (Total with disease). Rearranging the formula: Total with disease = 30 / 0.15 = 200. Thus, 200 individuals in the cohort had the disorder.
5. In the context of genetic screening, what is the primary trade-off when attempting to maximize a test's sensitivity?
   Answer: A likely decrease in the test's specificity. When you encounter questions about diagnostic test performance, focus on the fundamental relationship between sensitivity and specificity. These two measures are typically inversely related due to how diagnostic thresholds work. Sensitivity measures a test's ability to correctly identify positive cases (true positives), while specificity measures its ability to correctly identify negative cases (true negatives). To maximize sensitivity, you typically lower the threshold for calling a result "positive," which means you'll catch more true positive cases but also incorrectly classify more negative cases as positive. This trade-off means that as sensitivity increases, specificity generally decreases. Answer A is correct because this inverse relationship between sensitivity and specificity is a fundamental principle of diagnostic testing. When you make a test more sensitive, you inevitably reduce its specificity. Answer B is incorrect because increasing sensitivity doesn't necessarily require making the test more expensive or complex—it often just involves adjusting the interpretation threshold of existing results. Answer C represents a misunderstanding: maximizing sensitivity actually decreases false negatives (cases missed by the test), not increases them. Answer D is wrong because higher sensitivity doesn't inherently affect the scalability or efficiency of population screening—the same test can be applied to large populations regardless of its sensitivity setting. Remember this key principle: sensitivity and specificity exist in tension with each other. On genetics exams, when you see questions about optimizing one parameter of a diagnostic test, immediately consider what happens to the other parameter as a result of that optimization.
6. The graph shows distributions of a biomarker measurement for individuals with a genetic condition ('Affected') and without it ('Unaffected'). The vertical dashed line represents the diagnostic cutoff. If the cutoff is shifted to the right (to a higher biomarker level), what will be the effect on the test's performance?
   Answer: Sensitivity will decrease and specificity will increase. Shifting the cutoff to the right requires a higher biomarker level for a positive diagnosis. This will cause fewer affected individuals to meet the criterion, thus decreasing the number of true positives and increasing false negatives, which lowers sensitivity. Conversely, more unaffected individuals will now fall below the cutoff, increasing the number of true negatives and decreasing false positives, which raises specificity. Therefore, sensitivity will decrease and specificity will increase.
7. Which of the following scenarios describes a test with 100% specificity?
   Answer: No individual without the disease receives a positive test result. When you encounter questions about test performance metrics, focus on the precise definitions of sensitivity and specificity. Specificity measures a test's ability to correctly identify individuals who do NOT have the disease—it's all about avoiding false positives. A test with 100% specificity means that every person without the disease will test negative. In other words, there are zero false positives. Answer A captures this perfectly: "No individual without the disease receives a positive test result." This is the exact definition of perfect specificity. Let's examine why the other options are incorrect. Answer B describes sensitivity, not specificity—sensitivity measures how well a test identifies people who DO have the disease. Answer C describes positive predictive value (PPV), which tells you the probability that a positive test result is truly positive, but this depends on disease prevalence, not just specificity. Answer D also describes sensitivity by focusing on false negatives; false negatives occur when diseased individuals test negative, which relates to the test's ability to detect disease. The key distinction is that specificity is about the test's performance in healthy individuals, while sensitivity is about performance in diseased individuals. Remember this simple framework: specificity = "specific to negatives" (correctly identifying non-diseased people), while sensitivity = "sensitive to positives" (correctly identifying diseased people). When you see "100% specificity," immediately think "zero false positives among healthy people."
8. A diagnostic test for a genetic condition correctly identifies 450 out of 500 affected individuals and correctly identifies 880 out of 1000 unaffected individuals. Which statement accurately describes the test's performance?
   Answer: The false positive rate is higher than the false negative rate. When you encounter diagnostic test questions, you need to calculate four key metrics from the data: sensitivity, specificity, and the false positive and false negative rates. From the given data, let's identify our values: - True positives (TP): 450 affected individuals correctly identified - False negatives (FN): 50 affected individuals missed (500 - 450) - True negatives (TN): 880 unaffected individuals correctly identified - False positives (FP): 120 unaffected individuals incorrectly identified as positive (1000 - 880) Now we can calculate: - Sensitivity = TP/(TP + FN) = 450/500 = 90% - Specificity = TN/(TN + FP) = 880/1000 = 88% - False positive rate = FP/(FP + TN) = 120/1000 = 12% - False negative rate = FN/(FN + TP) = 50/500 = 10% The false positive rate (12%) is indeed higher than the false negative rate (10%), making D correct. A is wrong because it reverses the sensitivity and specificity values. B is incorrect since true negatives (880) are greater than true positives (450). C is backwards—the test actually has higher sensitivity (90%) than specificity (88%), meaning it's better at confirming disease than ruling it out. Remember this pattern: always set up your 2×2 table first, then calculate each metric systematically. False positive and false negative rates are often the key comparisons that determine the correct answer in diagnostic test questions.
9. A new non-invasive prenatal test for a specific chromosomal abnormality is evaluated. In a trial cohort of 5,000 pregnancies, 100 were confirmed to have the abnormality by amniocentesis. The new test correctly identified 90 of these cases. Among the 4,900 unaffected pregnancies, the test reported a negative result for 4,802. What is the specificity of this new test?
   Answer: 98.0% Specificity is the ability of a test to correctly identify those without the disease. It is calculated as True Negatives / (True Negatives + False Positives). In this cohort, there are 4,900 unaffected pregnancies. The test correctly identified 4,802 of them as negative (True Negatives). The number of False Positives is the number of unaffected pregnancies that tested positive, which is 4,900 - 4,802 = 98. Therefore, specificity = 4,802 / (4,802 + 98) = 4,802 / 4,900 = 0.98 or 98.0%.
10. The sensitivity and specificity of a diagnostic test are considered to be intrinsic properties. If a test with known sensitivity and specificity is applied to a new population where the prevalence of the genetic disease is five times higher, how will the test's sensitivity change?
    Answer: It will remain unchanged. When you encounter questions about diagnostic test performance, remember that sensitivity and specificity are intrinsic properties of the test itself—they don't change based on the population being tested. These measures reflect how well the test performs under controlled conditions. Sensitivity measures the test's ability to correctly identify people who actually have the disease (true positive rate), while specificity measures its ability to correctly identify people who don't have the disease (true negative rate). These properties depend on the test's biological or technical characteristics, not on how common the disease is in different populations. The correct answer is D because sensitivity remains unchanged regardless of disease prevalence. A test that correctly identifies 90% of affected individuals will continue to do so whether the disease affects 1 in 1,000 people or 5 in 1,000 people. Choice A incorrectly suggests sensitivity varies with prevalence—this confuses sensitivity with positive predictive value, which does change with prevalence. Choice B misunderstands the relationship between true positives and sensitivity; while higher prevalence means more true positives in absolute numbers, the proportion of diseased individuals correctly identified stays constant. Choice C incorrectly implies that specificity affects sensitivity or that you need additional information—sensitivity and specificity are independent measures. Remember this key distinction: sensitivity and specificity are properties of the test itself, while positive and negative predictive values are what change when you apply that same test to populations with different disease prevalence rates.
11. In a validation study for a new genetic marker for a type of cancer, 200 known cancer patients and 800 healthy controls were tested. The test was positive for 180 of the cancer patients and 40 of the healthy controls. What is the sensitivity of this new test?
    Answer: 90.0% Sensitivity is the proportion of individuals with the disease who test positive. It is calculated as True Positives / (True Positives + False Negatives). Here, the number of individuals with the disease is 200. The number of true positives (diseased individuals who test positive) is 180. The number of false negatives (diseased individuals who test negative) is 200 - 180 = 20. Thus, sensitivity = 180 / (180 + 20) = 180 / 200 = 0.90 or 90.0%.
12. A genetic test for an autosomal dominant condition has a sensitivity of 95% and a specificity of 90%. If this test is used on a population of 10,000 people, where 500 individuals have the condition, how many people will receive a false positive result?
    Answer: 950 This is a multi-step problem. First, determine the number of people without the condition: 10,000 (total) - 500 (with condition) = 9,500. Specificity is the proportion of disease-free individuals who test negative. A specificity of 90% means the false positive rate is 100% - 90% = 10%. False positives occur in the disease-free group. Therefore, the number of false positives is 10% of 9,500, which is 0.10 * 9,500 = 950.
13. Two new genetic tests are available for a certain condition. Test A has a sensitivity of 99% and specificity of 85%. Test B has a sensitivity of 85% and specificity of 99%. A patient has already received a positive result from a low-cost, broadly used screening test with high sensitivity. Which of the two new tests would be more appropriate to use as a confirmatory test?
    Answer: Test B, because its high specificity is needed to rule out false positives. The initial screening test was highly sensitive, meaning it was good at detecting potential cases but likely produced a number of false positives. The purpose of a confirmatory test is to rule out these false positives and confirm the diagnosis. This requires a test with high specificity, which is the ability to correctly identify individuals who do not have the disease. Test B, with its 99% specificity, is therefore the ideal choice.
14. A genetic test for susceptibility to a certain disease yields 25 false positive results in a group of 1,000 disease-free individuals. What is the specificity of this test?
    Answer: 97.5% Specificity is the proportion of disease-free individuals who test negative. The total number of disease-free individuals is 1,000. We are given that there are 25 false positives (FP). The number of true negatives (TN) is the total number of disease-free individuals minus the false positives: TN = 1,000 - 25 = 975. Specificity is calculated as TN / (TN + FP) = 975 / (975 + 25) = 975 / 1,000 = 0.975 or 97.5%.
15. A study reports that a genetic screening test has a specificity of 98%. Which of the following is the most accurate interpretation of this statement?
    Answer: 2% of individuals without the disease will receive a positive test result. When you encounter questions about diagnostic test performance, you need to distinguish between four key metrics: sensitivity, specificity, positive predictive value, and negative predictive value. Specificity specifically measures how well a test correctly identifies people who do NOT have the disease. Specificity of 98% means that out of 100 people without the disease, 98 will correctly test negative and 2 will incorrectly test positive (false positives). This directly supports answer D: 2% of individuals without the disease will receive a positive test result. Let's examine why the other options are incorrect. Answer A describes sensitivity, not specificity – sensitivity measures the percentage of people with the disease who test positive. Answer B describes positive predictive value, which tells you what percentage of positive test results are true positives (this depends on both specificity and disease prevalence in the population). Answer C is incorrect because the 2% error rate only applies to people without the disease, not the entire tested population – the total misclassification rate would depend on how many people in the study actually had the disease. Remember this key distinction: sensitivity focuses on catching the disease when it's present ("sensitive" to disease), while specificity focuses on correctly ruling out disease when it's absent ("specific" for no disease). A simple memory trick: "SpPin" – high Specificity rules IN disease when positive, and "SnNout" – high Sensitivity rules OUT disease when negative.
16. A manufacturer claims their new genetic test for a recessive disorder has a sensitivity of 99.9%. In a clinical setting, this means that the test is exceptionally good at:
    Answer: Ensuring that almost every individual with the disorder receives a positive result. When you encounter questions about genetic test performance, focus on understanding what sensitivity and specificity actually measure. Sensitivity tells you how well a test identifies people who have the condition, while specificity tells you how well it identifies people who don't have the condition. A sensitivity of 99.9% means that out of 1,000 people who actually have the recessive disorder, the test will correctly identify 999 of them as positive. In other words, the test is exceptionally good at catching nearly everyone who has the disorder - which makes D correct. Let's examine why the other options miss the mark. Option A describes specificity, not sensitivity - minimizing false alarms in healthy people relates to correctly identifying those without the disorder. Option B also confuses the concepts; a test's ability to confirm absence of disease when negative depends on negative predictive value, which involves both sensitivity and disease prevalence. Option C refers to positive predictive value, which depends heavily on disease prevalence in the population and involves both sensitivity and specificity working together. The key trap here is that options A, B, and C all describe important test characteristics, but they're not what sensitivity measures. Sensitivity is specifically about the test's ability to be positive when the disease is present - essentially asking "if someone has the disorder, what's the chance the test will catch it?" Remember this simple distinction: sensitivity = catching the sick, specificity = clearing the healthy. High sensitivity means few people with the disease will be missed.
17. The calculation of a test's sensitivity requires the number of true positives (TP) and false negatives (FN). The value of the denominator in the sensitivity formula (TP + FN) represents which of the following groups?
    Answer: The total number of individuals who truly have the condition. When evaluating diagnostic tests in genetics, understanding sensitivity helps you assess how well a test identifies individuals who actually have a genetic condition. Sensitivity measures the proportion of true cases that the test correctly identifies as positive. The sensitivity formula is: $\text{Sensitivity} = \frac{\text{TP}}{\text{TP + FN}}$ The denominator (TP + FN) represents all individuals who truly have the condition being tested for. Think about it logically: true positives are people with the condition who test positive, while false negatives are people with the condition who test negative. Together, these two groups make up everyone who actually has the condition, regardless of their test results. Looking at the incorrect options: Option B describes those who tested positive (TP + FP), which would be the denominator for positive predictive value, not sensitivity. Option C refers to all correctly classified individuals (TP + TN), which relates to overall test accuracy. Option D simply describes the entire study population, which includes all four categories of test outcomes. The key insight is that sensitivity specifically measures how well a test performs among those who have the condition. It asks: "Of all the people who actually have this genetic condition, what percentage does our test successfully identify?" This makes sensitivity particularly important in genetics when you need to ensure that individuals with serious hereditary conditions aren't missed. Remember: sensitivity focuses on the condition-positive population, while specificity focuses on the condition-negative population. Keep these denominators straight by thinking about which group each metric is designed to evaluate.
18. A research paper states that a new screening test for a mitochondrial disorder has a false negative rate of 5%. What does this imply about the test's performance?
    Answer: The test's sensitivity is 95%. The false negative rate (FNR) is the proportion of individuals with the disease who test negative (FN / (TP + FN)). Sensitivity is the proportion of individuals with the disease who test positive (TP / (TP + FN)). Since every individual with the disease either tests positive (TP) or negative (FN), the sum of these proportions must be 1. Therefore, Sensitivity = 1 - FNR. If the FNR is 5% (0.05), the sensitivity is 1 - 0.05 = 0.95, or 95%.
19. For a newborn screening program aimed at detecting a rare, treatable metabolic disorder where early intervention is critical to prevent severe intellectual disability, which test characteristic is of the highest priority?
    Answer: High sensitivity, to ensure no affected newborns are missed. In a screening scenario for a serious but treatable disease, the primary goal is to identify all affected individuals. Therefore, high sensitivity (a low false-negative rate) is the most critical characteristic. The consequence of a false negative (missing a case) is severe and irreversible damage. While high specificity is also desirable to reduce false positives, it is secondary to ensuring that all true cases are caught for treatment.

Start this quiz